---
title: Publications
---



## IMPROVE Project
You can view the documentation for the IMPROVE project [here](/https://jdacs4c-improve.github.io/docs/).

The Hallmarks of Predictive Oncology  
*Cancer Discovery, 2025*  
*Singhal A, Zhao X, Wall P, So E, Calderini G, Partin A, **Koussa N**, Vasanthakumari P, Narykov O, Zhu Y, Jones SE, Abbas-Aghababazadeh F, Kadambat Nair S, Bélisle-Pipon JC, Jayaram A, Parker BA, Yeung KT, Griffiths JI, Weil R, Nath A, Haibe-Kains B, Ideker T.*  
[Pubmed](https://pubmed.ncbi.nlm.nih.gov/39760657/)


## Nussenzweig Lab

Comprehensive mapping of cell fates in microsatellite unstable cancer cells support dual targeting of WRN and ATR.  
*Genes & Development, 2023*  
*Zong D, **Koussa NC**, Cornwell JA, Pankajam AVA, Kruhlak MJ, Wong N, Chari R, Cappell SD, Nussenzweig A.*  
[Pubmed](https://pubmed.ncbi.nlm.nih.gov/37932011/)

S1-END-seq reveals DNA secondary structures in human cells.  
*Molecular Cell, 2022*  
*Matos-Rodrigues G, van Wietmarschen N, Wu W, Tripathi V, **Koussa NC**, Pavani R, Nathan WJ, Callen E, Belinky F, Mohammed A, Napierala M, Usdin K, Ansari AZ, Mirkin SM, Nussenzweig A.*  
[Pubmed](https://pubmed.ncbi.nlm.nih.gov/36075220/)



## Smith Lab

Post-replicative nick translation occurs on the lagging strand during prolonged depletion of DNA ligase I in Saccharomyces cerevisiae.    
*G3 Genes|Genomes|Genetics, 2021*  
***Koussa NC**, Smith DJ.*  
[Pubmed](https://pubmed.ncbi.nlm.nih.gov/34849819/)

Limiting DNA polymerase delta alters replication dynamics and leads to a dependence on checkpoint activation and recombination-mediated DNA repair.  
*PLoS Genetics, 2021*  
***Koussa NC**, Smith DJ.*  
[Pubmed](https://pubmed.ncbi.nlm.nih.gov/33493195/)

Separable, Ctf4-mediated recruitment of DNA Polymerase α for initiation of DNA synthesis at replication origins and lagging-strand priming during replication elongation.  
*PLoS Genetics, 2020*  
*Porcella SY, **Koussa NC**, Tang CP, Kramer DN, Srivastava P, Smith DJ.*  
[Pubmed](https://pubmed.ncbi.nlm.nih.gov/32379761/)



## Baselga Lab

Pten loss promotes MAPK pathway dependency in HER2/neu breast carcinomas.  
*Proceedings of the National Academy of Sciences, 2016*  
*Ebbesen SH, Scaltriti M, Bialucha CU, **Morse N**, Kastenhuber ER, Wen HY, Dow LE, Baselga J, Lowe SW.*  
[Pubmed](https://pubmed.ncbi.nlm.nih.gov/26929372/)

Taselisib (GDC-0032), a Potent beta-Sparing Small Molecule Inhibitor of PI3K, Radiosensitizes Head and Neck Squamous Carcinomas Containing Activating PIK3CA Alterations.  
*Clinical Cancer Research, 2016*  
*Zumsteg ZS, **Morse N**, Krigsfeld G, Gupta G, Higginson DS, Lee NY, Morris L, Ganly I, Shiao SL, Powell SN, Chung CH, Scaltriti M, Baselga J.*  
[Pubmed](https://pubmed.ncbi.nlm.nih.gov/26589432/)

AXL mediates resistance to PI3Kα inhibition by activating the EGFR/PKC/mTOR axis in head and neck and esophageal squamous cell carcinomas.  
*Cancer Cell, 2015*  
*Elkabets M, Pazarentzos E, Juric D, Sheng Q, Pelossof RA, Brook S, Benzaken AO, Rodon J, **Morse N**, Yan JJ, Liu M, Das R, Chen Y, Tam A, Wang H, Liang J, Gurski JM, Kerr DA, Rosell R, Teixido C, Huang A, Ghossein RA, Rosen N,  Bivona TG, Scaltriti M, Baselga J.*  
[Pubmed](https://pubmed.ncbi.nlm.nih.gov/25873175/)

PI3K inhibition results in enhanced estrogen receptor function and dependence in hormone receptor-positive breast cancer.  
*Science Translational Medicine, 2015*  
*Bosch A, Li Z, Bergamaschi A, Ellis H, Toska E, Prat A, Tao JJ, Spratt DE, Viola-Villegas NT, Castel P, Minuesa G, **Morse N**, Rodón J, Ibrahim Y, Cortes J, Perez-Garcia J, Galvan P, Grueso J, Guzman M, Katzenellenbogen JA, Kharas M, Lewis JS, Dickler M, Serra V, Rosen N, Chandarlapaty S, Scaltriti M, Baselga J.*  
[Pubmed](https://pubmed.ncbi.nlm.nih.gov/25877889/)

Antagonism of EGFR and HER3 enhances the response to inhibitors of the PI3K-Akt pathway in triple-negative breast cancer.  
*Science Signaling, 2014*  
*Tao JJ*, Castel P*, Radosevic-Robin N, Elkabets M, Auricchio N, Aceto N, Weitsman G, Barber P, Vojnovic B, Ellis H, **Morse N**, Viola-Villegas NT, Bosch A, Juric D, Hazra S, Singh S, Kim P, Bergamaschi A, Maheswaran S, Ng T, Penault-Llorca F, Lewis JS, Carey LA, Perou CM, Baselga J, Scaltriti M.*  
[Pubmed](https://pubmed.ncbi.nlm.nih.gov/24667376/)

mTORC1 inhibition is required for sensitivity to PI3K p110α inhibitors in PIK3CA-mutant breast cancer.  
*Science Translational Medicine, 2013*  
*Elkabets M*, Vora S*, Juric D*, **Morse N**, Mino-Kenudson M, Muranen T, Tao J, Campos AB, Rodon J, Ibrahim YH, Serra V, Rodrik-Outmezguine V, Hazra S, Singh S, Kim P, Quadt C, Liu M, Huang A, Rosen N, Engelman JA, Scaltriti M, Baselga J.*  
[Pubmed](https://pubmed.ncbi.nlm.nih.gov/23903756/)


